€48.26
1.57% today
Xetra, Nov 14, 01:44 pm CET
ISIN
DE0005785604
Symbol
FRE

Fresenius Stock price

€49.03
+0.97 2.02% 1M
+6.72 15.88% 6M
+15.49 46.18% YTD
+16.22 49.44% 1Y
+24.87 102.94% 3Y
+11.72 31.41% 5Y
-18.39 27.28% 10Y
+36.00 276.32% 20Y
Xetra, Closing price Thu, Nov 13 2025
-0.74 1.49%
ISIN
DE0005785604
Symbol
FRE

New AI Insights on Fresenius Insights AI Insights on Fresenius

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
€27.7b
Enterprise Value
€37.8b
Net debt
€10.0b
Cash
€2.8b
Shares outstanding
563.2m
Valuation (TTM | estimate)
P/E
24.9 | 14.4
P/S
1.2 | 1.2
EV/Sales
1.7 | 1.7
EV/FCF
29.6
P/B
1.5
Dividends
DPS
€1.00
Yield 1Y | 5Y
2.0% | 2.2%
Growth 1Y | 5Y
100.0% | 3.6%
Payout 1Y | 3Y
120.5% | 86.5%
Increased
1 Year
Financials (TTM | estimate)
Revenue
€22.2b | €22.8b
EBITDA
€2.3b | €3.8b
EBIT
€2.2b | €2.6b
Net Income
€1.1b | €1.9b
Free Cash Flow
€1.3b
Growth (TTM | estimate)
Revenue
0.9% | 4.6%
EBITDA
75.0% | 109.2%
EBIT
76.4% | 46.2%
Net Income
200.9% | 308.3%
Free Cash Flow
-57.1%
Margin (TTM | estimate)
Gross
25.4%
EBITDA
10.1% | 16.7%
EBIT
9.9%
Net
5.1% | 8.4%
Free Cash Flow
5.7%
Financial Health
Equity Ratio
44.9%
Return on Equity
2.4%
ROCE
6.7%
ROIC
5.0%
Debt/Equity
0.7
More
EPS
€2.0
FCF per Share
€2.3
Short interest
-
Employees
176k
Rev per Employee
€120.0k
Show more

Create a Free Account to create an Fresenius alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Fresenius Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Fresenius forecast:

21x Buy
91%
2x Hold
9%

Analyst Opinions

23 Analysts have issued a Fresenius forecast:

Buy
91%
Hold
9%

Financial data from Fresenius

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
22,228 22,228
1% 1%
100%
- Direct Costs 16,581 16,581
2% 2%
75%
5,647 5,647
9% 9%
25%
- Selling and Administrative Expenses 2,853 2,853
12% 12%
13%
- Research and Development Expense 602 602
4% 4%
3%
2,252 2,252
75% 75%
10%
- Depreciation and Amortization 44 44
26% 26%
0%
EBIT (Operating Income) EBIT 2,208 2,208
76% 76%
10%
Net Profit 1,125 1,125
201% 201%
5%

In millions EUR.

Don't miss a Thing! We will send you all news about Fresenius directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fresenius Stock News

AD HOC NEWS
5 days ago
Deutsche Bank Research hat das Kursziel für Fresenius DE0005785604 von 53 auf 56 Euro angehoben und die Einstufung auf "Buy" belassen.
AD HOC NEWS
10 days ago
Die Schweizer Großbank UBS hat die Einstufung für Fresenius DE0005785604 nach Zahlen mit einem Kursziel von 57 Euro auf "Buy" belassen.
AD HOC NEWS
19 days ago
Deutsche Bank Research hat das Kursziel für Fresenius DE0005785604 von 52 auf 53 Euro angehoben und die Einstufung auf "Buy" belassen.
More Fresenius News

Company Profile

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products, and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, Fresenius Vamed, and Corporate and Other. The Fresenius Medical Care segment comprises dialysis products and healthcare services. The Fresenius Kabi segment specializes intravenous drugs, clinical nutrition, infusion therapy, medical devices, and transfusion technology. The Fresenius Helios focuses on the private hospital operations. The Fresenius Vamed segment manages projects and services for hospitals and other healthcare facilities. The Corporate and Other segment includes the holding activities. The company was founded by Eduard Fresenius in October 1912 and is headquartered in Bad Homburg, Germany.

Head office Germany
CEO Michael Sen
Employees 176,486
Founded 1912
Website www.fresenius.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today